Related Experiment Video
Updated: May 22, 2025
08:13
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
67.7K
The Oral Glucose Tolerance Test: Changed Results Using Different Drinking Solutions?
Sabine Schipf1, Oliver Kuß2,3,4, Barbara Thorand3,5,6
1Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.
Summary
Two oral glucose tolerance test (oGTT) solutions, a commercial Accu-Chek Roche and a standardized NRF 13.8, showed no significant clinical differences in 2-hour glucose levels or gastrointestinal side effects. This finding supports the interchangeability of these solutions in diagnostic testing.
Area of Science:
- Endocrinology
- Clinical Chemistry
- Public Health Research
Background:
- The choice of drinking solution for oral glucose tolerance tests (oGTT) can influence results and patient experience.
- Standardized protocols are crucial for accurate diabetes diagnosis and management.
Purpose of the Study:
- To compare the impact of a commercial Accu-Chek Roche solution versus a standardized NRF 13.8 oGTT solution on 2-hour glucose values.
- To assess and compare gastrointestinal side effects associated with each oGTT solution.
Main Methods:
- A subgroup of German National Cohort (NAKO) participants received either the Accu-Chek Roche or NRF 13.8 solution for a 75g oGTT.
- Participants were matched by study center, sex, age, BMI, and fasting glucose.
- 2-hour glucose values were analyzed using intra-class correlations and Bland-Altman plots; coefficients of variation were also calculated.
Main Results:
- The mean difference in 2-hour glucose between the two solutions was -3.4 mg/dL, with no systematic pattern in variability.
- Intra-class correlations for 2-hour glucose were 22%, and coefficients of variation were similar (25% for both).
- Gastrointestinal symptoms like nausea or vomiting occurred in less than 0.1% of participants, with no significant difference between solutions.
Conclusions:
- The Accu-Chek Roche and NRF 13.8 oGTT solutions yield comparable 2-hour glucose values and gastrointestinal side effect profiles.
- These findings suggest that both solutions are clinically interchangeable for performing oral glucose tolerance tests.
More Related Videos
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
140
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
140
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
148
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
148
01:06Oral Hypoglycemic Agents: Glinides
124
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
124
01:15Hypoglycemia and Glucagon
146
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
146
01:02Glucose Homeostasis: Regulation of Blood Glucose
1.3K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.3K
01:23Dipeptidyl Peptidase 4 Inhibitors
153
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
153